Floatz logo

Lis-Dexamphetamine

Attention Deficit Hyperactivity Disorder

Duke UniversityPhase 4 / ApprovedDormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Attention Deficit Hyperactivity Disorder cohort.

Asset / SponsorPhaseRating
Methylphenidate
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Phase 4BBB
Methylphenidate
St. Jude Children's Research Hospital
Phase 4BB
Olanzapine
Washington University School of Medicine
Phase 4BB
Mixed Salts Amphetamine
University of Cincinnati
Phase 4BB
Dextromethorphan
Prof. Dr. Frank Behrens
Phase 2CCC

View all 11 →

Same molecule, other indications

Lis-Dexamphetamine is also rated in:

glucose intoleranceDormant
B
Indicative ·
60 / 100
View asset →
obesity disorderDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →